| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgical Oncology (LAN, SES, HMK, FCA, MIR, KKH), Medical Breast Oncology (AUB), and Radiation Oncology (TB), The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Correspondence: Address correspondence and reprint requests to: Kelly K. Hunt, MD, FACS, Associate Professor of Surgery, Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 444, Houston, TX 770300-4009; Fax: 713-792-4689; E-mail: khunt{at}mail.mdanderson.org
Background: The role of preoperative chemotherapy for breast cancer is evolving. We initiated a prospective trial of sequential preoperative paclitaxel and doxorubicin–based combination chemotherapy in patients with stage I (tumor >1 cm), II, or IIIA disease and evaluated its effect on breast-conservation therapy (BCT) eligibility.
Methods: Pathology findings for the initial 100 consecutive patients who underwent surgery were analyzed.
Results: The median tumor size at presentation was 2.4 cm, and 39% of patients were deemed eligible for BCT. After chemotherapy, the median tumor size decreased to 1.0 cm (P < .001), and 59% of patients seemed BCT eligible (BCT conversion rate 34% among patients initially assessed as BCT ineligible; P < .001). Final pathology confirmed BCT feasibility in 90% of patients assessed as BCT candidates before surgery. The pathology from mastectomy specimens revealed BCT feasibility in 11 (27%) of 41 patients deemed BCT ineligible. Multivariate analysis revealed lobular histology, multicentricity, and calcifications, but not age, initial tumor size, or nodal status to predict final pathology indicating BCT ineligibility.
Conclusions: Induction chemotherapy improves BCT eligibility for breast cancer patients. Improved breast imaging methods after chemotherapy are necessary to improve accuracy in predicting the feasibility of BCT, especially in patients presenting with diffuse calcifications or multicentricity.
Key Words: Breast cancer • Induction chemotherapy • Lumpectomy • Breast-conservation surgery
This article has been cited by other articles:
 |
|
 |
|
  S. Loibl, G. von Minckwitz, G. Raab, J.-U. Blohmer, S. D. Costa, B. Gerber, H. Eidtmann, S. Petrich, J. Hilfrich, C. Jackisch, et al. Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial Ann. Surg. Oncol., November 1, 2006; 13(11): 1434 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Peintinger, H. M. Kuerer, K. Anderson, J. C. Boughey, F. Meric-Bernstam, S. E. Singletary, K. K. Hunt, G. J. Whitman, T. Stephens, A. U. Buzdar, et al. Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy Ann. Surg. Oncol., November 1, 2006; 13(11): 1443 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, and L. A. Newman Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy Ann. Surg. Oncol., September 1, 2005; 12(9): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sadetzki, B. Oberman, D. Zipple, B. Kaufman, S. Rizel, I. Novikov, and M. Z. Papa Breast Conservation After Neoadjuvant Chemotherapy Ann. Surg. Oncol., June 1, 2005; 12(6): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Abrial, I. Van Praagh, R. Delva, B. Leduc, J. Fleury, E. Gamelin, I. Sillet-Bach, F. Penault-Llorca, S. Amat, and P. Chollet Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer Oncologist, April 1, 2005; 10(4): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Newman and H. M. Kuerer Advances in Breast Conservation Therapy J. Clin. Oncol., March 10, 2005; 23(8): 1685 - 1697. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Thibault, C. Nos, M. Meunier, C. El Khoury, L. Ollivier, B. Sigal-Zafrani, and K. Clough MRI for Surgical Planning in Patients with Breast Cancer Who Undergo Preoperative Chemotherapy Am. J. Roentgenol., October 1, 2004; 183(4): 1159 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Chen, F. Meric-Bernstam, K. K. Hunt, H. D. Thames, M. J. Oswald, E. D. Outlaw, E. A. Strom, M. D. McNeese, H. M. Kuerer, M. I. Ross, et al. Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience J. Clin. Oncol., June 15, 2004; 22(12): 2303 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al. Reanalysis of Cancer Drugs: Old Drugs, New Tricks Clin. Cancer Res., June 1, 2004; 10(11): 3897 - 3907. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Korkola, S. DeVries, J. Fridlyand, E. S. Hwang, A. L. H. Estep, Y.-Y. Chen, K. L. Chew, S. H. Dairkee, R. M. Jensen, and F. M. Waldman Differentiation of Lobular versus Ductal Breast Carcinomas by Expression Microarray Analysis Cancer Res., November 1, 2003; 63(21): 7167 - 7175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Newman, N. L. Pernick, V. Adsay, K. A. Carolin, P. I. Philip, S. Sipierski, D. L. Bouwman, M. A. Kosir, M. White, and D. W. Visscher Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome Ann. Surg. Oncol., August 1, 2003; 10(7): 734 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Bland Utilization of Sentinel Lymph Node Mapping to Determine Pathologic Outcomes for Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 217 - 219. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
